SCHEMBL4087186

SCHEMBL4087186

NC(=O)c1cnc(N2CCNCC2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 5/20 0.51
HDAC2 Q92769 8/20 0.51
HDAC3 O15379 6/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C18 P33260 1/20 0.50
CYP2C19 P33261 1/20 0.50
KCNH2 Q12809 1/20 0.50
OGA O60502 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
HDAC1 Q13547 4/20 0.47
HDAC4 P56524 2/20 0.46
HDAC7 Q8WUI4 2/20 0.46
HDAC10 Q969S8 2/20 0.46
HDAC11 Q96DB2 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC9 Q9UKV0 2/20 0.46
HDAC5 Q9UQL6 2/20 0.46
SNCA P37840 1/20 0.42
CHRNB2 P17787 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146195 0.86 HDAC2 (0.52) SCDHDAC2HDAC3CYP1A2CYP2C18
SCHEMBL28997099 0.81 SCD (0.51) SCDHDAC2HDAC3OGAHRH3
SCHEMBL3131659 0.81 SCD (0.51) SCDHDAC2HDAC3OGAHRH3
SCHEMBL16859156 0.81 TDP1 (0.56) SCDHDAC2HDAC3KCNH2OGA
SCHEMBL28539361 0.81 HDAC2 (0.47) SCDHDAC2HDAC3CYP1A2CYP2C18
SCHEMBL4092990 0.81 CRBN (0.55) HDAC2HDAC3CYP1A2CYP2C18CYP2C19
SCHEMBL31474329 0.81 HDAC2 (0.56) SCDHDAC2HDAC3CYP1A2CYP2C18
SCHEMBL16496524 0.80 SCD (0.59) SCDHDAC2HDAC3OGAHRH3
Hydrochloric Acid SCHEMBL29215320 0.80 HDAC2 (0.54) SCDHDAC2HDAC3CYP1A2CYP2C18
Hydrochloric Acid SCHEMBL2828121 0.80 HDAC2 (0.45) SCDHDAC2HDAC3CYP1A2CYP2C18

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099200-A1 Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase MERCK FROSST CANADA LTD. (CA) 2009-04-16 US disclosed
CN-101228156-A Fungicidal carboxamides DU PONT (US) 2008-07-23 CN disclosed
EP-1902051-A1 AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Frosst Canada Ltd. (CA) 2008-03-26 EP disclosed
WO-2006130986-A1 AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099200-A1 Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase SCD, SCD5, SREBF1 SCD 1/4885HDAC2 645/4885HDAC3 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.